表皮生长因子受体单克隆抗体与肿瘤免疫治疗

• 作 者: 章卫平 曹雪涛 杨嗣坤
• 机 构: 第二军医大学免疫学教研室,第二军医大学免疫学教研室,第二军医大学免疫学教研室
• 出 处: 国外医学(免疫学分册)
• 发表日期: 1993年02期
• 关键词: 肿瘤免疫治疗 单克隆抗体 细胞生长 生长抑制作用 皮样癌 体内外试验 Ⅰ期临床试验 乳腺癌细胞 恶性增殖 免疫毒素

表皮生长因子受体(EGF-R)在多种上皮样癌细胞表面过度表达.其与配体TGF-a/EGF结合后,能促进细胞分裂增殖;它与癌基因v-erB编码的蛋白高度同源,与肿瘤的发生、发展密切相关.EGF-R单克隆抗体可竞争性阻抑EGF-R与其配体的结合,体内外试验均证明它对多种肿瘤细胞具有剂量依赖性生长抑制作用,经Ⅰ期临床试验取得了一定的抗肿瘤效果.EGF-R单抗可望成为一种安全可行、有效的肿瘤免疫治疗新途径.

Epidermal growth factor receptor (EGF-R) is over-expressed on the surface of a variety of epithelioid carcinoma cells. After binding to ligand TGF-a/EGF, it can promote cell division and proliferation; it is highly encoded by the oncogene v-erB. The homology is closely related to the occurrence and development of tumors. EGF-R monoclonal antibody can competitively inhibit the binding of EGF-R to its ligand. Both in vivo and in vitro tests have demonstrated that it has a dose-dependent growth inhibitory effect on a variety of tumor cells. After a period of clinical trials have achieved a certain anti-tumor effect. EGF-R monoclonal antibody is expected to become a safe and feasible and effective new ways of tumor immunotherapy.